AbbVie Inc. (ABBV) operating KPIs
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)
Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%
AbbVie ozurdex (dexamethasone intravitreal implant) — Worldwide net revenues ($M) ($M)
Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues
Latest, Q4 2025
128
Period ended Dec 31, 2025
Change on a year earlier
+6.7%
120 in Q4 2024
History
16 quarters
Since Q1 2022
Sources
11
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Ozurdex (dexamethasone intravitreal implant) — Worldwide net revenues ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2025 | Dec 31, 2025 | 128 | +6.7% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2025 | Sep 30, 2025 | 117 | -1.7% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 30, 2025 | 125 | +0.8% | Form 10-Q (filed 2025-08-04) ↗ |
| Q1 2025 | Mar 31, 2025 | 123 | -6.1% | Form 10-Q (filed 2025-05-09) ↗ |
| Q4 2024 | Dec 31, 2024 | 120 | +1.7% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2024 | Sep 30, 2024 | 119 | -0.8% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 124 | +4.2% | Form 10-Q (filed 2025-08-04) ↗ |
| Q1 2024 | Mar 31, 2024 | 131 | +13.9% | Form 10-Q (filed 2025-05-09) ↗ |
| Q4 2023 | Dec 31, 2023 | 118 | +12.4% | Form 10-K (filed 2026-02-20) ↗ |
| Q3 2023 | Sep 30, 2023 | 120 | +13.2% | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2023 | Jun 30, 2023 | 119 | +8.2% | Form 10-Q (filed 2024-08-07) ↗ |
| Q1 2023 | Mar 31, 2023 | 115 | +7.5% | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2022 | Dec 31, 2022 | 105 | – | Form 10-K (filed 2025-02-14) ↗ |
| Q3 2022 | Sep 30, 2022 | 106 | – | Form 10-Q (filed 2023-11-06) ↗ |
| Q2 2022 | Jun 30, 2022 | 110 | – | Form 10-Q (filed 2023-08-07) ↗ |
| Q1 2022 | Mar 31, 2022 | 107 | – | Form 10-Q (filed 2023-05-05) ↗ |
Breakdown
What makes up ozurdex (dexamethasone intravitreal implant) — worldwide net revenues ($m)
- Ozurdex (dexamethasone intravitreal implant) — U.S. net revenues ($M)32 · Q4 2025
- Ozurdex (dexamethasone intravitreal implant) — International net revenues ($M)96 · Q4 2025
- Ozurdex (dexamethasone intravitreal implant) — Worldwide reported growth YoY (%)6.9% · Q4 2025
- Ozurdex (dexamethasone intravitreal implant) — Worldwide operational (constant-currency) growth YoY (%)4.3% · Q4 2025
Cite this data
StockData. (2026). AbbVie Ozurdex (dexamethasone intravitreal implant) — Worldwide net revenues ($M) ($M), quarterly Q1 2022–Q4 2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/ozurdex_ww
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.